Fig. 2: Progression free and overall survival according to the presence of CPC in the autograft.
From: Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients
A PFS in the entire cohort. B OS in the entire cohort. C PFS in the subgroup of patients with ≥VGPR prior to transplant. D OS in the subgroup of patients with ≥VGPR prior to transplant.
